Abstract:Objective: To assess the current literature for blinatumomab in the treatment of adult and pediatric B-cell acute lymphoblastic leukemia (ALL). Data sources: We conducted a PubMed (inception to December 11, 2020) and ClinicalTrials.gov systematic literature search using the following terms: blinatumomab, Blincyto, lymphoblastic leukemia, and bispecific T-cell engager. Study selection and data extraction: All relevant published articles, package inserts, and meeting abstracts evaluating the use of blinatumomab in ALL were considered for inclusion. Data synthesis: Blinatumomab, a first-in-class bispecific T-cell engager monoclonal antibody, facilitates cytotoxic T-cell activation and subsequent eradication of CD19-positive B cells. The confirmatory phase III TOWER trial demonstrated superior overall survival (OS) with blinatumomab compared with standard chemotherapy (7.7 months vs 4.0 months) in relapsed and refractory (R/R) B-cell ALL. In the phase II BLAST trial, blinatumomab achieved a complete measurable residual disease (MRD) response in 78% of evaluable patients, with a median OS of 36.5 months. Potentially life-threatening cytokine release syndrome and neurotoxicity occurred in approximately 15% and 65% of patients, respectively. Relevance to patient care and clinical practice: Following initial Food and Drug Administration approval in 2014, blinatumomab gained expanded approval in pediatric patients and in Philadelphia chromosome-positive R/R ALL. In 2018, blinatumomab became the first and only drug approved for the treatment of persistent MRD in any hematologic malignancy. Emerging data demonstrate promising efficacy with blinatumomab in specific ALL settings, including frontline therapy, as a bridge to transplantation, and in "chemotherapy-free" combination regimens. Conclusions: Blinatumomab provides a paradigm-shifting treatment option; however, many questions surrounding optimal patient selection, sequencing, and cost-effectiveness remain.

Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens

Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia

Efficacy and Safety of Blinatumomab in Chinese Adults with Ph-negative Relapsed/refractory B-cell Precursor Acute Lymphoblastic Leukemia: A Multicenter Open-Label Single-Arm China Registrational Study

Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients

Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms

Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab

Recent advances and novel treatment paradigms in acute lymphocytic leukemia

A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions

Treatment of adult acute lymphoblastic leukemia (ALL) with a focus on emerging investigational and targeted therapies

Cytogenetic guided therapy using blinatumomab and inotuzumab ozogamicin in a patient with relapse/refractory acute lymphoblastic leukemia

Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia

Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia

Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes

Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions

Novel Immunotherapies for Adult Patients with B-lineage Acute Lymphoblastic Leukemia

Blinatumomab: A New Treatment for Adults With Relapsed Acute Lymphocytic Leukemia

Novel Management Options for Adult Patients With Progressive Acute Lymphoblastic Leukemia: A Case-Study Compendium

Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia

Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia

SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia

Recent updates for antibody therapy for acute lymphoblastic leukemia